SELLAS Life Sciences Group Inc. (SLS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.15 (-2.17% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #812 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, SRPT (Sarepta Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and GENB (Generate Biomedicines Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.02B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $0 in revenue, -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 60% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SLS currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.16) and Max Pain ($10.66) forces dealer call-delta covering toward $16.67.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SELLAS Life Sciences Group Inc. (SLS) dropped -2.17% to $10.15, trading at 60% of its 52-week range ($1.39 – $15.88). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
SELLAS Life Sciences Group (SLS) has entered a pivotal moment after its Phase 3 REGAL trial of galinpepimut-S reached the pre-set 80th event, which triggered the final analysis of overall survival data. Recent trading te
Retail bulls discussed buying the dip and a potential buyout, while others also challenged survival estimates.
Sellas said that its Phase 3 Regal trial of GPS recorded its 80th event, triggering the final analysis.
Key TakeawaysSellas shares fell 18% today after the company said its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, which triggers the trial’s final analysis. The drop looks like investors selling
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.
- Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SELLAS Li
SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SELLAS Life Sciences Group Inc. (SLS) ranks #812 by composite RQD confidence (35/100, grade D-) and #257 by equity capitalization ($2.05B). Within this direct 5-issuer industry benchmark cohort, SLS leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with SLS at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLS
ACTIVE
SELLAS Life Sciences Group Inc. | D- | 35/100 | — | — | -21.8% | -2.17% | $2.05B | Benchmark Subject |
| SRPT Sarepta Therapeutics Inc. | D- | 35/100 | — | 96.0% | -35.0% | -0.47% | $2.03B | /srpt-vs-sls → |
| GENB Generate Biomedicines Inc. | C- | 61/100 | — | — | — | +2.54% | $2.02B | /genb-vs-sls → |
| ZYME Zymeworks Inc. | D | 47/100 | — | — | -32.2% | -0.66% | $2.02B | /zyme-vs-sls → |
| SEPN Septerna Inc. | C | 62/100 | — | — | -20.7% | +2.22% | $2.11B | /sepn-vs-sls → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.9M, operating cash flow of -$28.4M, and free cash flow of -$28.4M (+19.8% YoY). On the balance sheet, SLS closed FY2025 with $78.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$26.9M | -$28.4M | -$28.4M | $78.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$30.9M | -$35.4M | -$35.4M | $19.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.3M | -$31.4M | -$31.4M | — | — |
As of 2026-11-01, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.15 (-2.17% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #812 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, SRPT (Sarepta Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and GENB (Generate Biomedicines Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.02B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $0 in revenue, -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SLS last traded at $10.15 (-2.17% on volume of 8,357,909 shares), positioning the stock -16.53% below its 50-day simple moving average ($12.16) and +18.44% above its 200-day simple moving average ($8.57). Across its 52-week range of $1.39 to $15.88, SLS sits at the 60.5% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.88 to $11.42).
Why SLS Stock dropped -2.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.